Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations

被引:23
|
作者
Le, V. N. P. [1 ,2 ]
Robins, E. [3 ]
Flament, M. P. [1 ,2 ]
机构
[1] Univ Lille Nord France, Coll Pharm, Lille, France
[2] INSERM U 1008, Lille, France
[3] APTAR Pharma, F-27100 Le Vaudreuil, France
关键词
Gas permeation; DPI performance; Fluticasone; Agglomerates; Powder aerosolisation; IN-VITRO DEPOSITION; SALMETEROL XINAFOATE; LACTOSE CARRIER; PARTICLE-SIZE; RESPIRABLE PARTICLES; AEROSOL DISPERSION; SURFACE-PROPERTIES; DRUG; INHALATION; MIXTURES;
D O I
10.1016/j.ejpb.2011.12.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Due to their small size, the respirable drug particles tend to form agglomerates which prevent flowing and aerosolisation. A carrier is used to be mixed with drug in one hand to facilitate the powder flow during manufacturing, in other hand to help the fluidisation upon patient inhalation. Depending on drug concentration, drug agglomerates can be formed in the mixture. The aim of this work was to study the agglomeration behaviour of fluticasone propionate (FP) within interactive mixtures for inhalation. The agglomerate phenomenon of fluticasone propionate after mixing with different fractions of lactose without fine particles of lactose (smaller than 32 pm) was demonstrated by the optical microscopy observation. A technique measuring the FP size in the mixture was developed, based on laser diffraction method. The FP agglomerate sizes were found to be in a linear correlation with the pore size of the carrier powder bed (R-2 = 0.9382). The latter depends on the particle size distribution of carrier. This founding can explain the role of carrier size in de-agglomeration of drug particles in the mixture. Furthermore, it gives more structural information of interactive mixture for inhalation that can be used in the investigation of aerosolisation mechanism of powder. According to the manufacturing history, different batches of FP show different agglomeration intensities which can be detected by Spraytec (R), a new laser diffraction method for measuring aerodynamic size. After mixing with a carrier, Lactohale LH200, the most cohesive batch of FP, generates a lower fine particle fraction. It can be explained by the fact that agglomerates of fluticasone propionate with very large size was detected in the mixtures. By using silica-gel beads as ball-milling agent during the mixing process, the FP agglomerate size decreases accordingly to the quantity of mixing aid. The homogeneity and the aerodynamic performance of the mixtures are improved. The mixing aid based on ball-milling effect could be used to ameliorate the quality of inhalation mixture of cohesive drug, such as fluticasone propionate. However, there is a threshold where an optimal amount of mixing aids should be used. Not only the drug des-aggregation reaches its peak but the increase in drug-carrier adhesion due to high energy input should balance the de-agglomeration capacity of mixing process. This approach provides a potential alternative in DPI formulation processing. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:596 / 603
页数:8
相关论文
共 50 条
  • [31] CFD DEM ANALYSIS OF A DRY POWDER INHALER
    Badhan, Antara
    Kotteda, V. M. Krushnarao
    Kumar, Vinod
    PROCEEDINGS OF THE ASME/JSME/KSME JOINT FLUIDS ENGINEERING CONFERENCE, 2019, VOL 2, 2019,
  • [32] The Role of Force Control Agents in High-Dose Dry Powder Inhaler Formulations
    Begat, Philippe
    Morton, David A. V.
    Shur, Jagdeep
    Kippax, Paul
    Staniforth, John N.
    Price, Robert
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) : 2770 - 2783
  • [33] Aerodynamic deposition of combination dry powder inhaler formulations in vitro: A comparison of three impactors
    Taki, Mohammed
    Marriott, Christopher
    Zeng, Xian-Ming
    Martin, Gary P.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 388 (1-2) : 40 - 51
  • [34] Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler
    Yeung, Stewart
    Traini, Daniela
    Tweedie, Alan
    Lewis, David
    Church, Tanya
    Young, Paul M.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (02) : 949 - 959
  • [35] Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations
    Guchardi, R.
    Frei, M.
    John, E.
    Kaerger, J. S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 348 (1-2) : 10 - 17
  • [36] Powder dispersion mechanisms within a dry powder inhaler using microscale particle image velocimetry
    Kou, Xiang
    Wereley, Steven T.
    Heng, Paul W. S.
    Chan, Lai Wah
    Carvajal, M. Teresa
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 514 (02) : 445 - 455
  • [37] Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations
    Hertel, Mats
    Schwarz, Eugen
    Kobler, Mirjam
    Hauptstein, Sabine
    Steckel, Hartwig
    Scherliess, Regina
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 535 (1-2) : 59 - 67
  • [38] Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations
    Donovan, Martin J.
    Smyth, Hugh D. C.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 402 (1-2) : 1 - 9
  • [40] The 'stage-by-stage' deposition of drugs from commercial single-active and combination dry powder inhaler formulations
    Taki, Mohammed
    Ahmed, Sarah
    Marriott, Christopher
    Zeng, Xian-Ming
    Martin, Gary P.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 43 (04) : 225 - 235